Vaccine and infection myocarditis risks contrasted A new Immunisation Coalition chart illustrates the much higher myocarditis risks following COVID-19 infection compared to vaccination.
Stronger myocarditis warnings after death linked to vaccine The stronger product information warning follows the death of a woman in her 20s, who died after receiving a Moderna booster.
TGA releases vaccine-related myocarditis severity details Fewer than 1% of all likely myocarditis or pericarditis cases linked to mRNA vaccines in Australia have been treated in intensive care.
Boosters’ Omicron impact outlined in vaccination tool update GPs and patients can now generate personalised information on the risks and benefits associated with choosing whether or not to receive a booster shot.
More than 40 children given incorrect dose of COVID-19 vaccine No serious adverse effects were reported among the tiny proportion of children aged 5–11 who received an adult dose.
Teenage social patterns make boosters a ‘good idea’, expert says GPs are soon expected to start administering booster doses to those aged 16–17 following the TGA’s provisional approval of Pfizer.
COVID-19 chart updated with Omicron risk of death, benefits of boosters GPs can now access up-to-date data on the benefits of booster doses for patients who have received AstraZeneca as their primary course based on risks of Omicron transmission.
COVID risk calculator updated to include Pfizer vaccine, myocarditis probability New data has been added to the online tool, which is designed to help GPs and their patients assess the risks and benefits of vaccination.
TGA releases updated COVID booster safety data Swollen lymph nodes have been the most commonly reported adverse effect to emerge from Australia’s booster program.
COVID vaccination for children aged 5–11 to begin in January Pfizer’s paediatric vaccine has received its final approval, with ATAGI’s clinical guidance recommending a dosage interval of eight weeks.